Antibody-Cytokine Combinations With Philogen's Dr. Dario Neri
Business Of Biotech
00:00
Regulatory Gempy Manufacturing
Pelo says it was a strategic decision not to go to c dmo. The company has the intellectual capacity and facilities infor structure to handle development on its own, he adds. Once you have set it up, this is obviously a barrier to the entry, but there is also a cost saving factor,. Plus you can do manufacturing also for partners. And so this is one of the things i am most proud of we took there of setting it up.
Transcript
Play full episode
